

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 13th April 2023, 1-3pm

Virtual meeting

Name	Title	Organisation	Representing	Oct	Nov	Dec	Feb	Mar	Apr
Dr Helen Burgess (HB)	GP MO Prescribing lead	GM ICB - Manchester	GPs	✓	✓	✓	✓	✓	✓
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	✓	✓	✓	A	✓	✓
Kate Rigden (KR)	Chief Finance Officer	GM ICB	ICB finance	✓	✓	A	✓	✓	✓
Mina Patel (MP)	Trust Finance Officer	MFT	Provider Finance	✓	✓	✓	✓	✓	✓
Jay Hamilton (TBC)	Programme lead	HiM	Health Innovation Manchester (HiM)	A	A	✓	A	A	✓
Dr Ann Harrison (AH)	GP MO Prescribing lead	GM ICB - Trafford	GPs	✓	✓	✓	A	✓	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	✓	A	✓	✓	✓	✓
Dr Pete Budden	GP Prescribing lead	GM ICB - Salford	GMMMG Clinical Reference Subgroup	A	✓	✓	✓	✓	A
Aneet Kapoor	Chair of the GM LPN	LPN	Pharmacy profession	✓	✓	✓	✓	✓	✓
Vacant seat			GM Secondary Care Clinicians						
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	✓	✓	✓	✓

Chris Haigh (CH)	HOMM	GM ICB - Bolton	CCG MO leads and GMMMGS Digital subgroup	✓	✓	✓	✓	A	A
Luvjit Kandula (LK)	Chair – Community Pharmacy Provider Board (CPPB)	GM LPC	Community Pharmacy	✓	✓	✓	✓	✓	A
Lara Shah (LS)	Deputy HOMM	GM ICB - Manchester	GMMMGS Population health and inequalities subgroup	✓	✓	✓	A	A	A
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	GM ICB – commissioning (TBC)	CCG Commissioning lead	A	A	✓	✓	✓	✓
Kenny Li	GM Chief Pharmacist	GM ICB	GMMMGS Medicines Value subgroup	✓	✓	✓	✓	✓	✓
Faisal Bokhari or Heather Bury	HOMM	GM ICB – T&G NHS GM ICB	GMMMGS Pharmacy workforce subgroup	✓ H B	✓	✓ H B	✓ F B	✓ F B	✓
Karen O’Brien (KO’B)	Regional Pharmacist	NHSEI	NHSEI	A	✓	✓	✓	✓	✓
Paul Buckley (PaB)	Chief Pharmacist	Stockport FT	GM Chief pharmacists	✓	✓	✓	✓	✓	✓
Steve Simpson (SS)	Chief Pharmacist	Bolton FT	GM Chief pharmacists	✓	✓	✓	✓	✓	A
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	✓	✓	✓	✓	✓	✓
Anna Swift (AS)	Associate Director Medicines Management	GM ICB (Wigan)	GM antimicrobial stewardship group + GM diabetes board						✓
Claire Vaughan (CV)	Head of MO	GM ICB - Salford	Vice Chair of GMMMGS and GMMMGS Medicines Safety subgroup	✓	✓	✓	✓	✓	A
Dr Sanjay Wahie (SW)	Clinical Director	GM ICB - Wigan	GPs	✓	✓	✓	✓	✓	A
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strategic Clinical Network	✓	✓	✓	A	✓	✓
Vacant seat			Provider Board representative						

Vacant seat			Council representative for GM Social Services						
Vacant seat			GM Medical Directors						
Vacant seat			Lay representative						
Vacant seat			GM Public Health						
Monica Mason (MM)	Head of Prescribing Support	RDTC	Professional secretary	✓	✓	✓	✓	✓	✓
Andrew Martin (AM)	MO Pharmacist	GM Joint Commissioning team	GMMMGM support	✓	✓	✓	✓	✓	A
Dan Newsome (DN)	Principal pharmacist	RDTC	GMMMGM support	A	✓	✓	✓	✓	✓

1. General Business

1.1 Apologies

As above.

The group welcomed Anna Swift (associate director of MM at Wigan) to the GMMMGM membership. Anna currently co-chairs the GM antimicrobial stewardship group and taking up a seat on GMMMGM to represent this group, but also as the GMMMGM representative on the GM diabetes board which commences in May.

It was noted agreed that this meeting would only run for one hour to accommodate system pressures and holidays.

Declarations of Interest

Nil raised

2.0 Minutes and actions from the last meeting

Minutes from the March meeting were approved for publication. The group considered the outstanding actions as follows:

- Medicines value subgroup ToR (KL) – awaited
- GM ophthalmology pathway – KL explained that the draft pathway is out for consultation with the authors, it can be made available on request if anyone wishes to view this draft, it will be submitted to GMMMGM soon.
- KL is working with pharmacy leads and the executive finance team to try and obtain approval for the use of CGM in line with NICE guidance, GM wide.
- Delegation of specialised commissioning – CS explained that a NW region-wide meeting had taken place and it was understood that C&SL will be hosting this function for the NW. KO'B explained that the NW medicines optimisation group which is in development will also be involved in this, and any other NW "do once" priorities. There is no action for GMMMGM at this time and this item can be closed.

- Obesity treatments funding bid – MM updated the group on conversation with HiM through JH, and that GMMMGM can best support any initiatives that are brought to it at the earliest stage. The role of GMMMGM in ensuring robust governance was emphasised, but there was value in GMMMGM, Health Innovation Manchester and the Strategic Clinical Networks working more closely.

Concern was raised by a GMMMGM member concerning a recent PCN lipid initiative which appeared to have gone only through HiM governance and not ICB governance at locality level. The need for good governance and transparency was again emphasised by GMMMGM members.

It was accepted that JH would return a GMMMGM scoping paper to the next possible meeting to detail the work undertaken by HiM around obesity services capacity. JH would also update GMMMGM on the outcome of a HiM bid for funding for an obesity treatment pilot once announced.

- Shared care – KL is making contact with the mental health commissioners to discuss the issues raised previously around the commissioning of adult ADHD services. There was no update available from the central team around the adoption of the national shared care protocol.
- GM Medicines value plan – KL and KR updated on the discussions undertaken and the progress made since the last meeting, particularly around costing methodologies, and the presentation of primary and secondary care prescribing budgets and spend across GM. GMMMGM await submission of this plan.

Later the group discussed the group asked where cost saving initiatives could be considered. KL explained that it should go through the locality first and then if it is a GM initiative then it should be submitted to the medicines value group. KR explained that through the STAR process GM ICB were considering some investments, and locality leads would be able to support initiatives through this process which had been extended until the end of April.

- It was understood that all GMMMGM recommendations made at the March meeting were accepted by the ICB executive, this includes the recommendation around the acceptance of NICE appraised medicines.
- Members noted that the workforce paper presented at the March meeting is now open for GM wide consultation via the GMMMGM website.
- The prescribed medicines associated with withdrawal and dependency framework published by NHSE has been taken to the GMMMGM medicines safety group for action.

3.0 Medicines decisions for ratification (Mar)

GMMMGM approved all the recommendations presented for submission to CEGC April meeting (included TA853 and TA854). Any decisions with a financial impact will be submitted from CEGC to executive.

Action: RDTCC to publish decisions upon receipt of CEGC approval and where necessary executive approval.

4.0 GMMMGM response to the GM diabetes strategy

GMMMGM has taken up the invitation to accept a seat on the GM diabetes board, where the GM diabetes strategy is being developed. The terms of reference for this board and the GM diabetes strategy were presented to GMMMGM, who were asked to engage with their respective networks and return comments to the May meeting. GMMMGM will then generate a response to the strategy which AS can deliver to the board at the next appropriate meeting.

It was noted that the strategy states that GMMMGM is responsible for developing local guidelines for the intensification of medication for the control of diabetes, as well as monitoring and report against these guidelines with the aim of reducing unwarranted variation.

CV had also presented a helpful analysis of the strategy that had been undertaken for the Salford locality, it was recognised that only some of this function was the role of GMMMGM, and that this analysis would be useful if discussed by locality leads also.

Action: all members to gather the views of their networks and return these to the May meeting to support the development of a response by GMMMGM to the diabetes board.

5.0 Digital subgroup: progress paper

CH was unavailable for this meeting, so the report was received for information but discussion was reserved for a future meeting when CH is present.

Action: MM to explain to CH that this paper was received for information only and to seek a date to reschedule discussion.

6.0 The Hewitt Review - An independent review of integrated care systems

It is understood that this report is being discussed within the ICB, and was noted at this stage for information by GMMMMG pending further direction from the ICB executive.

AOB

- Nothing raised

Date of next meeting: Thursday 11th May 2023, 1 – 3pm